Vir Biotechnology, Inc. (VIR)

US — Healthcare Sector
Peers: CVAC  RETA  KRYS  PPCB  ISEE  BPMC  AMLX  KRTX  DAWN  VKTX  ICPT  TERN  AKRO  PTCT  MDGL 

Automate Your Wheel Strategy on VIR

With Tiblio's Option Bot, you can configure your own wheel strategy including VIR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VIR
  • Rev/Share 0.1427
  • Book/Share 7.5931
  • PB 0.6954
  • Debt/Equity 0.0921
  • CurrentRatio 6.7903
  • ROIC -0.5119

 

  • MktCap 729896640.0
  • FreeCF/Share -3.0708
  • PFCF -1.7291
  • PE -1.2565
  • Debt/Assets 0.0735
  • DivYield 0
  • ROE -0.4746

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
VIR
Published: May 09, 2025 by: Business Wire
Sentiment: Neutral

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB). The study-defined primary endpoint, proportion of participants with undetectable hepatitis B surface antigen (HBsAg) at 24 weeks post-end of treatment, was achieved by 17% (3/18) and 2.

Read More
image for news Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
VIR
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive

Vir Biotechnology, Inc.'s phase 3 ECLIPSE program for HDV, leveraging tobevibart and elebsiran, shows promise based on positive phase 2 SOLSTICE study results. The global hepatitis D market size is projected to surpass $1.05 billion by 2034. VIR-5518 and VIR-5500 are dual-masked HER2 and PSMA T-cell engagers being developed to target solid tumors; The current status of these candidates is that dose-escalation for both are ongoing.

Read More
image for news Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
VIR
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Nick Gasic - Leerink Partners Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co. Joseph Stringer - Needham & Company Operator Hello.

Read More
image for news Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
VIR
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago.

Read More
image for news Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
VIR
Published: April 24, 2025 by: Business Wire
Sentiment: Neutral

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran,.

Read More
image for news Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
VIR
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Hang Hu - Barclays Paul Choi - Goldman Sachs Phil Nadeau - TD Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham Patrick Trucchio - H.C. Wainwright & Co. Operator Hello.

Read More
image for news Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates
VIR
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.86 per share a year ago.

Read More
image for news Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates

About Vir Biotechnology, Inc. (VIR)

  • IPO Date 2019-10-11
  • Website https://www.vir.bio
  • Industry Biotechnology
  • CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
  • Employees 408

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.